Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.47 |
| ▸ | TP53 | P04637 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715035 | 0.82 | MAPT (0.48) | LMNATP53MAPTPOLBGAA | |
| SCHEMBL6714690 | 0.71 | GAA (0.53) | LMNATP53MAPTPOLBGAA | |
| SCHEMBL4629258 | 0.69 | RAB9A (0.65) | LMNATP53MAPTPOLBGAA | |
| SCHEMBL11328055 | 0.67 | LMNA (0.56) | LMNATP53MAPTPOLB | |
| SCHEMBL11322444 | 0.66 | LMNA (0.55) | LMNATP53MAPTPOLB | |
| SCHEMBL29982408 | 0.65 | CYP1A2 (0.62) | MAPTPOLBGAA | |
| SCHEMBL8939501 | 0.65 | CYP1A2 (0.62) | MAPTPOLBGAA | |
| SCHEMBL29150793 | 0.65 | TP53 (0.60) | LMNATP53MAPTPOLB | |
| SCHEMBL5784422 | 0.65 | TP53 (0.63) | LMNATP53MAPTPOLB | |
| SCHEMBL9549034 | 0.65 | TP53 (0.63) | LMNATP53MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | LMNA 3420/4885TP53 4773/4885MAPT 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.